19 August 2024
You are about to leave the Clinical Value website now.
Cancel
Continue
Liver Cancer
Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung…
Read Article
Turning the Tide Against Hep B and HCC: Insights from New Zealand’s…
Read Article
The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj…
Read Article
Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of…
A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC,…
Read ArticlePioneering Innovations in HCC Detection for Enhance Patient Outcomes –…
Turning the Tide Against Hep B and HCC: Insights from…
The Pursuit for Better Patient Outcomes – Innovating HCC Management…
Utility of Combining PIVKA-II and AFP in the Surveillance and…
Known also as the silent killer, chronic liver disease is big, complex and accelerating. Driven by viral infection, diet and lifestyle, 1.5 billion people worldwide are in jeopardy. Of these, 80% of new cases and 72% of total deaths occur in Asia alone.
From disease understanding, diagnostic testing, therapeutic treatments to monitoring – a new era of partnership and innovation provides the opportunity to improve the lives of millions of people around the world.
Expert Opinions
19 August 2024
Strategic Efficiencies: Evaluating Cost-Effectiveness of Biomarker-Based HCC Surveillance
30 July 2024
A Bold Stride Forward for Liver Health: Thailand’s Nationwide HBV Screening and EZ Liver Clinic
8 April 2024
Turning the Tide Against Hep B and HCC: Insights from New Zealand’s National Screening and Surveillance Program
13 February 2024
The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital
18 September 2023
Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective
In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…
READ MORE
23 June 2023
Leading the Way for HCC Surveillance and Diagnosis: Prof. Henry LY Chan
In this video, Prof Henry LY Chan, Deputy Chief Manager at Union Hospital Hong Kong, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…
READ MORE
19 May 2023
Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models
A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal "Research Review", covering at length topics such as non-alcoholic liver disease…
READ MORE
12 April 2023
PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu
In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…
READ MORE
13 March 2023
Leading the Way for HCC Surveillance and Diagnosis: Dr Bao Toan Nguyen
In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and…
READ MORE
9 December 2022
Liver Disease in Asia Pacific: Insights from Prof Pierce Chow
In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MORE
9 December 2022
Liver Disease and Patient Advocacy in Taiwan: Q&A with Prof Yang Pei-Ming
Liver disease is a serious public health issue in Taiwan. The Liver Disease Prevention and Treatment Research Foundation, Taiwan, is one of Asia’s most active and…
READ MORE
9 December 2022
Liver Cancer in Japan: Dr Shun Kaneko on HCC Screening and Surveillance
Japan is a global leader in hepatocellular carcinoma (HCC) surveillance, with an effective programme that enables early-stage carcinomas detection. Yet unmet needs continue to affect the…
READ MORE
9 December 2022
HCC in Thailand: Dr Terachai Songkiatkawin on Improving Liver Cancer Diagnostics and Treatment
More than 27,000 patients in Thailand are found to have liver cancer each year, making it the most-frequently diagnosed cancer in the country. With emerging risk…
READ MORE
9 December 2022
Tackling HCV in Punjab: local experts share strategies for success
Punjab is one of Pakistan’s largest provinces and has a particularly high HCV prevalence rate of roughly 9%, compared to 5.4% for Pakistan’s total population. Hear…
READ MORE
9 December 2022
Strengthening healthcare systems through the critical role of diagnostics
In line with the WHO Essential Diagnostics List (EDL) and Lancet Commission efforts, the Asia Pacific Medical Technology Association and its members recently came together to…
READ MORE
9 December 2022
Pakistan’s national HCV elimination programme: insights from Dr Huma Qureshi
In 2019, Pakistan announced a nationwide programme to scale up HCV prevention, testing and treatment. Hear from gastroenterologist Dr Huma Qureshi, a key figure in Pakistan’s…
READ MORE
9 December 2022
Hepatitis C: the patient journey from screening to diagnosis and treatment
An estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV), with a large proportion currently being undiagnosed or diagnosed late.…
READ MORE
9 December 2022
HCV screening in Egypt: key elements of a successful national screening programme
In 2018, the world’s largest HCV screening campaign was initiated in Egypt. Within 7 months following its initiation, 49.5 million people were screened; and 2.2 million…
READ MORE
9 December 2022
HCV elimination in Sindh: insights from Prof Muhammad Sadik Memon and Dr Zaigham Abbas
The province of Sindh has one of the world’s highest rates of HCV infection and bears the second highest disease burden of both HBV and HCV…
READ MORE
9 December 2022
HCV elimination in Northern Pakistan: Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands
Pakistan has one of the world’s highest rates of HCV infection. It's no surprise that their healthcare systems face mounting pressure from HCV-related conditions. Learn from…
READ MORE
9 December 2022
Future therapies for chronic Hepatitis B and the role of diagnostics
Hepatitis B is an important infectious disease problem in the APAC region. Learn from Prof Henry Chan, director of the Center for Liver Health at Chinese…
READ MOREKey Publications
27 June 2024
Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand
12 April 2024
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
20 March 2024
Development and Clinical Validation of a Novel Algorithmic Score (GAAD) for the Detection of Early-stage Hepatocellular Carcinoma
This study aims to establish and train the algorithm coefficients, and clinically validate the performance of the GAAD algorithm in differentiating HCC and benign chronic liver…
READ MORE
5 March 2024
Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis
2 October 2023
Patient-centric and ecosystem insights into hepatocellular carcinoma across Asia-Pacific – LEAP
In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and…
READ MORE
23 August 2023
Building modern hepatocellular carcinoma surveillance programmes: taking steps to address a leading cause of liver cancer death in Asia
In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…
READ MORE
19 June 2023
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…
READ MORE
19 June 2023
Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis
This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…
READ MORE
19 June 2023
The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data
The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data. Li B, Liu A, Wen Y, Yang…
READ MORE
19 June 2023
The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients. Xu F, Zhang L, He W,…
READ MORE
19 June 2023
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis
This systematic review and meta-analysis of cohort studies of patients with cirrhosis aimed to evaluate the benefit and harms of HCC surveillance in patients with cirrhosis.…
READ MORE
19 June 2023
Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer
The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal…
READ MORE
31 May 2023
APASL 2023 Taiwan Congress Report
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MORE
19 April 2023
Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma
This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…
READ MORE17 March 2023
Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region
A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and…
READ MORE
17 March 2023
Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis
This article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages…
READ MORE
17 March 2023
A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma
This study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Pang BY, Leng…
READ MORE
14 March 2023
Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE
14 March 2023
Biomarkers for the Early Detection of Hepatocellular Carcinoma
This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…
READ MORE
14 March 2023
Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE
14 March 2023
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.…
READ MORE
14 March 2023
Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
This study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…
READ MORE
14 March 2023
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…
READ MORE
14 March 2023
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), additional high-quality evidence has emerged with relevance to the diagnosis, staging,…
READ MORE
14 March 2023
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update
The 4th version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, and published in October 2017 in Japanese. New…
READ MORE
14 March 2023
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
Society guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. This study compared the performance of surveillance imaging,…
READ MORE
14 March 2023
Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature
HCC diagnosis can be particularly challenging in some cases and the obtained results seem ambiguous, resulting in a long-term and delayed diagnostic process.This paper presents three…
READ MORE
14 March 2023
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma
This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…
READ MORE
14 March 2023
Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…
READ MORE
13 March 2023
Hepatocellular carcinoma surveillance: current practice and future directions
This review article provides a comprehensive overview of the indications and rationale for HCC surveillance, currently available surveillance methods and their utilization, effectiveness, and limitations, as…
READ MORE
13 March 2023
Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis
PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of…
READ MORE
13 March 2023
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…
READ MORE
9 December 2022
The clinical utility of Elecsys GAAD score in the diagnosis of hepatocellular carcinoma
The performance of Elecsys® GAAD score, which includes the parameters of gender, age, alpha-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonists-II (PIVKA-II) in…
READ MORE
9 December 2022
Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This…
READ MORE
9 December 2022
Performance Evaluation of the Elecsys GAAD Assay for the Detection of Hepatocellular Carcinoma Across Different Disease Stages and Etiologies
The Elecsys® GAAD algorithm combines quantitative measurements of Elecsys PIVKA-II assay and Elecsys AFP assay, plus age and gender to generate a semi-quantitative result. This study…
READ MORE
9 December 2022
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study
This study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display…
READ MORE
9 December 2022
Elecsys PIVKA-II and Elecsys AFP assays demonstrate good clinical performance for hepatocellular carcinoma (HCC) diagnosis across different disease stages and aetiologies
This study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis…
READ MORE
9 December 2022
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify…
READ MORE
9 December 2022
APACMed White Paper – Strengthening Healthcare Systems Through the Critical Role of Diagnostics
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MORE
9 December 2022
Analytical performance and method comparison of the Elecsys PIVKA-II immunoassay as an aid in diagnosis of hepatocellular carcinoma (HCC)
This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a…
READ MORE
9 December 2022
A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort
This study compared the clinical performance of the Elecsys GALAD (gender [sex], age, alpha-fetoprotein [AFP] Lens culinaris agglutinin-reactive fraction of AFP [AFP-L3] and protein-induced by vitamin…
READ MOREWebinars and Symposiums
View the LEAD 2024 session recordings
APASL 2024 Kyoto Seminar
Watch the APASL 2024 seminar recording to hear experts share key updates on curative approaches to HCC management, treatment apporaches for BCLC-B uHCC, and real world…
READ MORE
ESMO Asia 2023 Symposium – HCC illuminated: Exploring future frontiers with systemic immunotherapies
Missed the satellite symposium session from ESMO Asia 2023? Access the webcast recording here.
READ MORE
Guiding the way: The role and value of algorithms in liver disease care journey
PIVKA-II in action: Clinical case studies on HCC surveillance and management
Panel discussion: Charting directions: Integrating new algorithms and approaches in practice
Navigating the Health Economic Data in APAC: Present challenges and future directions
HCC Surveillance in China: A Journey Towards Improving Patient Care and Outcomes
Real World Data Unveiled: Results and insights of GAAD in surveillance population
The Practice in Japan: Insights into gold standard HCC surveillance and management
APASL 2023 Taiwan Symposium
Watch the APASL 2023 symposium recording to hear experts share key updates on HCC surveillance, diagnosis, uHCC management and adj HCC systemic treatment.
READ MORE
Value of PIVKA-II in surveillance and treatment monitoring for patients with advanced HCC
This presentation has 2 parts. In the first part of this presentation, Prof. Nobuharu Tamaki discusses the diagnostic utility of PIVKA-II in HCC, and the potential…
READ MORE
HCC Patient Journey and biomarkers’ roles in the HCC management
Detection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from…
READ MORE
The clinical utility of HCC algorithms as aids in the diagnosis of HCC
In this presentation, Prof. Ming Lung Yu discusses the results of his study, which aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic…
READ MORE
Review of PIVKA-II expert consensus from APASL presentation
In this presentation, Prof. Do Young Kim reviews the results of the APAC expert consensus study on the utilization of PIVKA-II in the surveillance and monitoring…
READ MORE
APASL 2022 Seoul
The liver cancer landscape has been undergoing a period of rapid transformation. From early detection of HCC using new biomarkers, to new immunotherapy treatment options. Watch…
READ MORE
Global HCC Expert Series
Join our experts for a series of on-demand webinars, focused on clinical insights and knowledge from the fields of oncology, hepatology, interventional radiology, and surgery, to…
READ MORE
APPLE 2021 – Biomarker In HCC Surveillance And Treatment: The New Evidence On The Horizon
Join the webinar to hear speakers Prof. Henry Chan and Prof. Hui Chuan Sun as they discuss the use of PIVKA-II and GAAD score as promising…
READ MORE
APASL 2021 – The First Line Treatment in Unresectable HCC: From Evidence To Practice
Join the webinar to hear speakers Prof. Henry Chan, and Assoc. Prof. Teerha Piratvisuth as they discuss the clinical usefulness of PIVKA-II in HCC surveillance, as…
READ MOREDisease Awareness
22 April 2024
365 Cancer Prevention Society – Know Your Liver Webinar 2024
8 December 2022
My greatest hope | Mr Yan’s liver cancer story
Mr Yan was diagnosed with hepatocellular carcinoma (HCC) in 2018. He was a healthy, active person as a competitive skier, and his diagnosis was completely unexpected.…
READ MORE
8 December 2022
Hepatocellular carcinoma – the ‘silent killer’ disease infographic
Chronic liver disease (CLD) is on the rise. CLD can progress to Hepatocellular Carcinoma (HCC), a type of liver cancer. What are the risk factors for…
READ MORE
8 December 2022
Hepatocellular carcinoma – the ‘silent killer’ | Part 2
How did Taiwan halve the incidence of hepatocellular carcinoma (HCC) in a decade? HCC is the primary form of liver cancer, with 72% of cases diagnosed…
READ MORE
8 December 2022
Hepatocellular carcinoma – the ‘silent killer’ | Part 1
Do you know what can cause hepatocellular carcinoma, the primary form of liver cancer? In Asia, contaminated food has historically been linked with the disease and…
READ MORE
8 December 2022
Liver cancer: the global impact
Hepatocellular carcinoma numbers continue to rise globally, due to major risk factors such as Hepatitis B and C, and fatty liver disease. Hear Liver Patients International’s…
READ MORE
8 December 2022
Breaking the link between chronic liver disease and liver cancer
Millions of people are living with chronic liver disease. Can the link between chronic liver disease and liver cancer be broken through partnership?
READ MORE